Losartan Potassium Tablet, Film Coated
Product Images NDC 63187-357

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 63187-357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

63187-357-30 (Losartan25mg30s)

Label for Losartan Potassium 25 mg film-coated tablets, quantity of 30, by Proficient Rx LP. The label includes the NDC number 63187-357-30, dosage form as oral tablets, and storage instructions at 20°-25°C (68°-77°F). The tablets are described as white to off-white, oval-shaped, debossed with '1' and '5' on each side respectively. The manufacturer is Hetero Labs Limited, India.*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period between Losartan potassium (solid line) and Atenolol (dotted line). The graph shows a gradual increase in event rates for both drugs, with Losartan potassium consistently lower. It includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan potassium. The graph shows a lower stroke incidence for Losartan potassium, with an adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot titled 'Figure 3: Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol event rates for primary composite endpoints and fatal/non-fatal stroke across various demographics such as age, gender, race, ISH, diabetes, and history of cardiovascular disease. It shows event rates (%) and hazard ratios with 95% confidence intervals, indicating relative risk between the two drugs.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph showing the percentage of patients with an event over a 48-month period, comparing Losartan Potassium to placebo. The graph illustrates a risk reduction of 16.1% with Losartan Potassium, with corresponding p-value of 0.022, indicating statistical significance in favor of Losartan Potassium.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium, depicting its molecular framework including chlorinated ring, hydroxyl, and potassium salt groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.